Pre-exposure prophylaxis (PrEP) is a daily pill taken by HIV-negative people to prevent HIV infection. It can also be taken on demand before and after sex. The medicine stops the virus from getting ...

In 1999, NICE was set up to end the postcode lottery in access to medicines across the country – now healthtech is getting ...

NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

Our initiative centres on closer collaboration and information sharing between NICE and MHRA to enable parallel publication of decisions on licensing and value. The impact of this will be significant ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage ...

Pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75 mg to 150 mg of aspirin to take daily from 12 weeks until birth. Although this use is ...

There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with ...